GAST and metastatic neoplasm: In summary, the majority of patients had a KPS >90% at study entry (78%), metastatic disease (67%, stage IVB) from a pancreatic head primary (83%), and had not received previous chemotherapy or radiotherapy (one patient had previous immunisation against gastrin, which completed 6 weeks prior to study entry).